NCT06097390View on ClinicalTrials.gov

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

PHASE1CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

March 27, 2024

Conditions

Healthy Participants

Interventions

DRUG

Semaglutide

Oral administration

Trial Locations (1)

H3P 3P1

Altasciences Clinical Company, Inc, Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY